Wendell David Associates Inc. Sells 278 Shares of Thermo Fisher Scientific Inc. $TMO

Wendell David Associates Inc. cut its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 9.4% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,681 shares of the medical research company’s stock after selling 278 shares during the quarter. Wendell David Associates Inc.’s holdings in Thermo Fisher Scientific were worth $1,087,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of TMO. CBIZ Investment Advisory Services LLC lifted its stake in shares of Thermo Fisher Scientific by 137.5% in the first quarter. CBIZ Investment Advisory Services LLC now owns 57 shares of the medical research company’s stock worth $28,000 after acquiring an additional 33 shares during the period. Anderson Financial Strategies LLC acquired a new position in shares of Thermo Fisher Scientific in the first quarter worth approximately $30,000. Keystone Global Partners LLC acquired a new position in shares of Thermo Fisher Scientific in the first quarter worth approximately $31,000. DiNuzzo Private Wealth Inc. lifted its stake in shares of Thermo Fisher Scientific by 406.7% in the second quarter. DiNuzzo Private Wealth Inc. now owns 76 shares of the medical research company’s stock worth $31,000 after acquiring an additional 61 shares during the period. Finally, HighMark Wealth Management LLC lifted its stake in shares of Thermo Fisher Scientific by 140.6% in the second quarter. HighMark Wealth Management LLC now owns 77 shares of the medical research company’s stock worth $31,000 after acquiring an additional 45 shares during the period. 89.23% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of equities analysts recently commented on TMO shares. Barclays lifted their price objective on Thermo Fisher Scientific from $550.00 to $585.00 and gave the stock an “overweight” rating in a research note on Thursday, October 2nd. Robert W. Baird lifted their target price on Thermo Fisher Scientific from $553.00 to $567.00 and gave the stock an “outperform” rating in a report on Thursday, July 24th. Wells Fargo & Company lowered their target price on Thermo Fisher Scientific from $570.00 to $565.00 and set an “overweight” rating for the company in a report on Thursday, July 24th. Weiss Ratings reiterated a “hold (c)” rating on shares of Thermo Fisher Scientific in a report on Tuesday, October 14th. Finally, Royal Bank Of Canada set a $561.00 target price on Thermo Fisher Scientific and gave the stock an “outperform” rating in a report on Tuesday, September 2nd. Fifteen research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $589.10.

Thermo Fisher Scientific Price Performance

Shares of TMO opened at $539.05 on Friday. The business’s fifty day moving average is $495.74 and its 200 day moving average is $449.13. Thermo Fisher Scientific Inc. has a 12-month low of $385.46 and a 12-month high of $610.97. The company has a quick ratio of 1.50, a current ratio of 1.93 and a debt-to-equity ratio of 0.65. The stock has a market cap of $203.55 billion, a P/E ratio of 31.18, a P/E/G ratio of 2.93 and a beta of 0.77.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share for the quarter, topping the consensus estimate of $5.22 by $0.14. The firm had revenue of $10.86 billion for the quarter, compared to the consensus estimate of $10.68 billion. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The business’s revenue was up 2.9% on a year-over-year basis. During the same quarter in the prior year, the company posted $5.37 earnings per share. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Sell-side analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 400 shares of the business’s stock in a transaction that occurred on Friday, July 25th. The stock was sold at an average price of $479.98, for a total transaction of $191,992.00. Following the completion of the sale, the executive vice president directly owned 22,367 shares of the company’s stock, valued at approximately $10,735,712.66. The trade was a 1.76% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction that occurred on Friday, August 22nd. The shares were sold at an average price of $500.96, for a total value of $5,009,600.00. Following the completion of the transaction, the chief executive officer owned 115,174 shares in the company, valued at $57,697,567.04. This represents a 7.99% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 30,066 shares of company stock worth $14,182,963. Insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.